Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size

Series B

Verve Therapeutics turns to $94m series B
Novo and GV participated in a round that lifted the Harvard, Broad Institute and Penn-linked heart disease drug developer's overall funding to more than $215m.
BlueSphere Bio brings in $45.6m
Pitt spinout BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target size.
SpyGlass observes $27.5m
The eye disease device developer has raised series B funding to advance research originating from University of Colorado's s Sue Anschutz-Rodgers Eye Center.
LifeMine Therapeutics lands $50m
LifeMine’s chairman and co-founder Rick Klausner has co-led a round that included multiple corporates and pushed the overall equity to $120m.
Carisma motivates investors for $47m series B
IP Group was among the investors for UPenn-founded cancer immunotherapy developer Carisma Therapeutics, which has now raised nearly $109m altogether.
Werewolf wins over UPMC for series B
UPMC Enterprise has returned for a $72m series B round raised by Werewolf Therapeutics, which is now set to advance two lead assets through phase 1 trials.
Neuros Medical implants $38.5m
CWRU‘s pain neurostimulation spinout has secured series BB funding ahead of a 180-patient trial.
AMP Robotics accesses $55m in series B
UC-backed Congruent Ventures has contributed to a $55m round that will support the recycling robot maker's expansion plans.

Other News

The Engine helps pour $50m into Boston Metal
Boston Metal is most of the way to a $60m target for its latest round, thanks to a consortium that included returning backer The Engine.
Oxbotica takes series B for a $47m spin
University of Oxford’s autonomous driving software developer Oxbotica has secured $47m in a series B round featuring IP Group as well as several corporates.
Metcela tees up $12.7m
Utec has made its largest initial commitment to date by backing Keio-founded Metcela, a developer of cell therapies for heart disease.
Flexiv assembles $100m series B
Investors have thrown their backing behind a round topping $100m for Stanford-linked production automation robot developer Flexiv.
Singlera detects $150m in series B cash
Fudan University’s Furong Investment has co-led a round for Singlera Genomics, which will use the cash to advance its pipeline of cancer screening products.
Turing.com decodes $32m
Stanford-StartX Fund has backed Turing.com in a series B round that boosted the software developer sourcing platform’s overall funding to at least $46m.

Editor's Picks

Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Canvas paints $9m picture
Canvas Network, an online education platform developed by learning management software (LMS) provider Instructure which received $9.1m investment for the platform, has begun offering free and open online courses.
WRF finds its Resolve
In May 2010, Resolve raised $2m in the initial close of its A round before bringing in a corporate venturing unit later.
Imperial helps PsiOxus raise $34m
UK-listed investment fund Imperial Innovations joins GlaxoSmithKline's SR One, fund manager Invesco Perpetual and Lundbeckfond Ventures, backing the d cancer treatment company.
test reg

Login